{"id":868613,"date":"2025-07-10T16:34:27","date_gmt":"2025-07-10T20:34:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/"},"modified":"2025-07-10T16:34:27","modified_gmt":"2025-07-10T20:34:27","slug":"serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/","title":{"rendered":"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan"},"content":{"rendered":"
\n

HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson’s disease, enabled by its proprietary POZ Platform\u2122<\/sup>\u00a0drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina\u2019s common stock to a new non-executive employee on June 18, 2025 (the \u201cOption Grant\u201d).<\/p>\n

The Option Grant has an exercise price equal to the closing price of Serina\u2019s common stock on June 18, 2025. The Option Grant was offered as material inducement to the employee\u2019s employment. The Option Grant was approved by the Compensation Committee of Serina\u2019s Board of Directors on June 18, 2025, pursuant to Serina\u2019s 2024 Inducement Equity Plan to align their interests with Serina\u2019s stockholders and to promote the success of Serina\u2019s business.<\/p>\n

The Option Grant was made in reliance on the employment inducement exemption under the NYSE American\u2019s Company Guide Section 711(a) which requires public disclosure of inducement awards. Serina is issuing this press release pursuant to Section 711(a) of NYSE American\u2019s Company Guide.<\/p>\n

\n About Serina Therapeutics<\/strong>
\n \n <\/p>\n

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina\u2019s POZ Platform\u2122<\/sup>\u00a0provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.<\/p>\n

For more information, please visit\u00a0https:\/\/serinatherapeutics.com<\/a>.<\/p>\n

\n Cautionary Statement Regarding Forward-Looking Statement<\/strong>\n <\/p>\n

This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management\u2019s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina\u2019s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and\/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and\/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product\u2019s benefits outweigh its known risks and determination of the product\u2019s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and\/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, and Serina\u2019s other periodic reports and documents filed from time to time with the SEC.<\/p>\n

The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.<\/p>\n

\n For inquiries, please contact:<\/strong>\n <\/p>\n

Stefan Riley\u00a0
sriley@serinatherapeutics.com<\/a>
(256) 327-9630<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson’s disease, enabled by its proprietary POZ Platform\u2122\u00a0drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina\u2019s common stock to a new non-executive employee on June 18, 2025 (the \u201cOption Grant\u201d). The Option Grant has an exercise price equal to the closing price of Serina\u2019s common stock on June 18, 2025. The Option Grant was offered as material inducement to the employee\u2019s employment. The Option Grant was approved by the Compensation Committee of Serina\u2019s Board of Directors on June 18, 2025, pursuant … <\/p>\n

Continue reading “Serina Therapeutics Makes Grant to New Employee Under Inducement Plan”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-868613","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSerina Therapeutics Makes Grant to New Employee Under Inducement Plan - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson’s disease, enabled by its proprietary POZ Platform\u2122\u00a0drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina\u2019s common stock to a new non-executive employee on June 18, 2025 (the \u201cOption Grant\u201d). The Option Grant has an exercise price equal to the closing price of Serina\u2019s common stock on June 18, 2025. The Option Grant was offered as material inducement to the employee\u2019s employment. The Option Grant was approved by the Compensation Committee of Serina\u2019s Board of Directors on June 18, 2025, pursuant … Continue reading "Serina Therapeutics Makes Grant to New Employee Under Inducement Plan"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T20:34:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjQ4NCM3MDQyMDYzIzUwMDExOTk2NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan\",\"datePublished\":\"2025-07-10T20:34:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/\"},\"wordCount\":652,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MjQ4NCM3MDQyMDYzIzUwMDExOTk2NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/\",\"name\":\"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MjQ4NCM3MDQyMDYzIzUwMDExOTk2NQ==\",\"datePublished\":\"2025-07-10T20:34:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MjQ4NCM3MDQyMDYzIzUwMDExOTk2NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MjQ4NCM3MDQyMDYzIzUwMDExOTk2NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/","og_locale":"en_US","og_type":"article","og_title":"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan - Market Newsdesk","og_description":"HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (\u201cSerina\u201d) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson’s disease, enabled by its proprietary POZ Platform\u2122\u00a0drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina\u2019s common stock to a new non-executive employee on June 18, 2025 (the \u201cOption Grant\u201d). The Option Grant has an exercise price equal to the closing price of Serina\u2019s common stock on June 18, 2025. The Option Grant was offered as material inducement to the employee\u2019s employment. The Option Grant was approved by the Compensation Committee of Serina\u2019s Board of Directors on June 18, 2025, pursuant … Continue reading \"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-10T20:34:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjQ4NCM3MDQyMDYzIzUwMDExOTk2NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan","datePublished":"2025-07-10T20:34:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/"},"wordCount":652,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjQ4NCM3MDQyMDYzIzUwMDExOTk2NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/","name":"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjQ4NCM3MDQyMDYzIzUwMDExOTk2NQ==","datePublished":"2025-07-10T20:34:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjQ4NCM3MDQyMDYzIzUwMDExOTk2NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjQ4NCM3MDQyMDYzIzUwMDExOTk2NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/serina-therapeutics-makes-grant-to-new-employee-under-inducement-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Serina Therapeutics Makes Grant to New Employee Under Inducement Plan"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=868613"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868613\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=868613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=868613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=868613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}